Pricing Log in Create free account

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) vs Lyra Therapeutics, Inc. (LYRA)

Biodexa Pharmaceuticals PLC Unsponsored ADR and Lyra Therapeutics, Inc. are both Biotechnology companies. Lyra Therapeutics, Inc. is the larger, with a market value of $870.0K against $440.0K — 2.0× the size. Biodexa Pharmaceuticals PLC Unsponsored ADR grew revenue faster over the last twelve months: 60.2% against −74.1%. Biodexa Pharmaceuticals PLC Unsponsored ADR has the higher net margin (−1,155.7% vs −7,266.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Biodexa Pharmaceuticals PLC Unsponsored ADR leads on 11 and Lyra Therapeutics, Inc. on 4.

Valuation

Metric BDRX LYRA Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.74 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.20 0.51 0.64
EV/Sales (2.81) (39.19) 9.21
Earnings yield (555.04%) (10,078.95%) (33.15%)
Free cash flow yield 0.00% (9,793.95%) (25.50%)

Profitability

Metric BDRX LYRA Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (7,794.47%) 0.00%
Net margin (1,155.70%) (7,266.08%) 0.00%
Free cash flow margin 0.00% (7,261.06%) 0.00%
Return on equity 0.00% (6,594.98%) (56.36%)
Return on assets 0.00% (56.45%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BDRX LYRA Biotechnology median
Revenue growth (TTM) 60.22% (74.05%) 6.02%
EPS growth (last fiscal year) 89.68% 73.96% 30.26%
Revenue growth, 5-year CAGR (28.78%) (20.38%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BDRX LYRA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.41 1.71 4.72
Net debt to EBITDA 1.00 0.52 0.96

Dividend

Metric BDRX LYRA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BDRX LYRA Biotechnology median
Market cap 440.00k 870.00k 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack